Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review
Hui Wu, Zi-Heng Zhang, Ting Ye, Jia-Ni Chen, Tao-Hsin Tung, Jian-Sheng Zhu · 2026
Read Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review by Hui Wu, Zi-Heng Zhang, Ting Ye, Jia-Ni Chen, Tao-Hsin Tung, Jian-Sheng Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13253451.txt.
Description
Hui Wu and colleagues take stock of GLP-1 receptor agonists for fatty liver disease in a 2026 umbrella review. The disease, tied to metabolic dysfunction, is now the world's commonest chronic liver condition. GLP-1 drugs, developed for diabetes and obesity, act on metabolism in many tissues and are candidates to treat it, so the team reviewed the reviews.
Twenty-three reviews and meta-analyses were gathered and their quality appraised with a standard tool. Results were sorted into liver structure, liver enzymes, body measures, metabolic markers, and inflammation. Across these areas the drugs showed potential benefits with a broadly acceptable safety profile. The catch is evidence quality: nearly eighty percent of the included reviews rated critically low, and their underlying trials overlapped heavily. The authors therefore label their positive summary as preliminary. They call urgently for rigorous, independent trials before these drugs are adopted for liver disease on this basis.
Catalog record
| CREATOR | Hui Wu, Zi-Heng Zhang, Ting Ye, Jia-Ni Chen, Tao-Hsin Tung, Jian-Sheng Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |